Trial Profile
A Phase III, Long Term, Open Label, Follow on Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor 'Lomitapide' (LOMITAPIDE) in Patients With Homozygous Familial Hypercholesterolemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Feb 2023
Price :
$35
*
At a glance
- Drugs Lomitapide (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Aegerion Pharmaceuticals
- 01 Feb 2023 Results assessing long-term hepatic safety of lomitapide from phase III clinical studies and extension study: NCT00730236, NCT00943306 and NCT02135705 published in the Liver International
- 18 Jul 2017 Results of an open-label extension study assessing additional long-term efficacy and safety of lomitapide along with results of an exploratory post hoc analysis assessing the potential metabolic consequences of hepatic fat accumulation, published in the Circulation Journal as a research letter.
- 18 Mar 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.